Regulatory

Medicare Policies Must Fix Cost Sharing Under Part D, Expert Writes

May 4th 2022

By Mary Caffrey

Stacie B. Dusetzina, PhD, is the Ingram Associate Professor of Cancer Research at Vanderbilt University Medical Center, and a member of the editorial board for The American Journal of Managed Care®.

Julie Reed: House Hearing Omitted Biosimilar Issues Despite Growing Need for Solutions

May 4th 2022

By Skylar Jeremias

Video

The main takeaway from the House Energy and Commerce Committee hearing on HHS's 2023 budget was that biosimilars were not mentioned as much as they should have been, said Julie M. Reed of the Biosimilars Forum.

The US Is Entering Round 2 of Biosimilar Activity, Says Cardinal Health’s Oskouei

May 3rd 2022

By Laura Joszt

Article

The United States is about to enter round 2 of biosimilar activity with a pipeline that expands biosimilars into new therapeutic areas, said Sonia Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars, Cardinal Health, during her presentation at Asembia’s Specialty Pharmacy Summit.

Dr Eric Tichy Details Why More State Biosimilar Bills Are Needed

May 1st 2022

By Skylar Jeremias

Video

Eric Tichy, PharmD, MBA, vice chair of pharmacy formulary at the Mayo Clinic Health System, discusses the importance of state legislation to boost biosimilar access and uptake.

Dr Sarfaraz K. Niazi Claims Biosimilar Growth Signals Need for Greater Testing, Policy Reform

April 28th 2022

By Skylar Jeremias

Article

Now that the United States’ acceptance of biosimilars matches that in the European Union, developers should be encouraging changes to testing regulations to increase biosimilar accessibility, according to Sarfaraz K. Niazi, PhD, in his recent perspective paper.

Opinion: Biosimilar Adoption Will Help Achieve a Bipartisan Goal

April 25th 2022

By Robert Popovian, PharmD, MS

Article

Biosimilars provide significant savings and encourages competition in the biopharmaceutical marketplace but the United States needs to do more to empower uptake and address adoption barriers, according to Robert Popovian PharmD, MS.

Prioritizing Reference Products Over Biosimilars Led to Millions in Missed Savings for Part D

April 20th 2022

By Skylar Jeremias

Article

Medicare Part D plans missed out on between $84 million and $143 million in savings by not prioritizing the use of biosimilars over reference products, according to a report from the HHS Office of Inspector General.

Overseas Successes: Celltrion Launches in Canada, Wins Tender in Brazil

April 11th 2022

By Skylar Jeremias

Article

Republic of Korea-based Celltrion Healthcare launched its high-concentration adalimumab biosimilar in Canada and won several Brazilian tenders to supply its infliximab biosimilar.

Americans Say Drug Costs Are Too High, and They Are Right

April 2nd 2022

By Juliana M. Reed

Article

The executive director of the Biosimilars Forum calls for policies to support adoption of lower-cost biologics.

Review of Totality of Evidence for Infliximab Biosimilar ABP 710

March 30th 2022

By Deana Ferreri, PhD

Article

An article reviewed the totality of evidence leading to the approval of Amgen’s infliximab biosimilar ABP 710 (Avsola), which is currently approved in the US and Canada for all the indications of the originator (Remicade).